Becton, Dickinson and Company (BD) has reported a revenue of $5.1bn in the fourth quarter (Q4) of 2023, a 6.8% rise from $4.7bn in the corresponding period last year.
In the quarter, the company’s reported diluted earnings per share (EPS) from continuing operations were $0.53, a 42.4% decrease from the previous year's $0.92.
The quarter’s adjusted diluted EPS was $3.42, an increase of 24.4% from $2.75 in the same period last year.
The company's full-year revenue was $19.3bn, a 2.7% rise from the $18.87bn reported last year.
Its net income for the full year stood at $1.48bn, a 16.6% decrease from the $1.77bn reported in the corresponding period last year.
It anticipates revenues for the fiscal year 2024 (FY24) to fall between approximately $20.1bn and $20.3bn.
Furthermore, BD expects that the adjusted diluted EPS for FY24 will range from $12.70 to $13.00, a growth rate of roughly 4% to 6.5%.
BD chairman, CEO and president Tom Polen said: “We achieved another quarter and another year of strong performance through our talented team's execution of our BD2025 strategy and differentiated portfolio of medical technologies that are increasing healthcare efficiency and improving the lives of patients around the world.
“Looking ahead, continued execution of our category leadership strategy in higher-growth markets, advancement of our strong innovation pipeline and delivery against our simplification programmes position us well to deliver durable growth in FY24 and beyond.”
